“Hugo will be a growth driver for our surgical business and fiscal ‘26 and a meaningful growth driver for Medtronic in the mid-term.”

In context

“, and enhancing system performance. In international markets, utilization continues to increase, and we've more than doubled Hugo procedure volume year-over-year. In the U.S., we are on track to submit for FDA approval for Hugo with urology indications by the end of next month. I also have some new information to share with you today. We have finished enrollment in our hernia and benign GYN studies. Further, we recently received FDA approval to initiate our GYN oncology ID study and are actively moving that forward. We're also making progress adding features and instrumentation. We just completed our first cases using our ICG fluorescent imaging, and we expect to add our LigaSure Vessel Sealing technology to Hugo later this calendar year. So in total, we are confident in our path forward. Hugo will be a growth driver for our surgical business and fiscal ‘26 and a meaningful growth driver for Medtronic in the mid-term. Finally in diabetes we had our fifth quarter in a row of double-digit growth. We printed 10% growth on top of 10% growth in the prior year. Our growth is driven by one, the overall move of the market from standalone CGM with MDI, two AID systems; and two, the strength of our MiniMed 780G system within the AID category. We continue to grow our 780G installed base, and we're seeing very high CGM attachment rates, as well as strong growth and consumables. In Europe, we're getting excellent user feedback on our Simplera Sync sensor, which is half the size and much easier to apply than our previous sensor. In the U.S., we've submitted Simplera Sync for FDA approval, and we're also continuing to make progress on the integration work with the Abbott-based sensor. We expect these two new sensors”